Related Experiment Video
Updated: Jul 30, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Margetuximab in HER2-positive metastatic breast cancer
William J Gradishar1, Ruth O'Regan2, Mothaffar F Rimawi3
1Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA.
Abstract:
Several anti-HER2 agents are approved for third-line treatment and beyond (after first-line and second-line); however, no specific treatment strategy is recommended for third-line and beyond. Although these agents improve disease outcomes, HER2-positive metastatic breast cancer remains incurable and there is an unmet need for effective therapies in the later line setting. This review focuses on the development of margetuximab-cmkb, a novel, Fc-engineered, anti-HER2 monoclonal antibody, and its role in the systemic treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Insights
Margetuximab-cmkb is a novel anti-HER2 antibody for patients with HER2-positive metastatic breast cancer who have undergone prior treatments. It addresses the unmet need for effective therapies in later treatment lines.
Area of Science:
- Oncology
- Immunotherapy
- Breast Cancer Research
Background:
- Several anti-HER2 agents exist for advanced HER2-positive breast cancer, but no standard strategy is defined for third-line and beyond treatment.
- Despite current therapies, HER2-positive metastatic breast cancer remains incurable, highlighting an unmet need for novel treatments in later lines of care.
Purpose of the Study:
- This review examines the development and role of margetuximab-cmkb, an Fc-engineered anti-HER2 monoclonal antibody.
- The focus is on its application in systemic therapy for adult patients with metastatic HER2-positive breast cancer.
Main Methods:
- Review of scientific literature and clinical trial data on margetuximab-cmkb.
- Analysis of its mechanism of action as an Fc-engineered anti-HER2 antibody.
Main Results:
- Margetuximab-cmkb represents a novel therapeutic option for patients progressing after multiple anti-HER2 regimens.
- Its development targets the limitations of existing treatments in the refractory setting.
Conclusions:
- Margetuximab-cmkb offers a potential new treatment strategy for patients with metastatic HER2-positive breast cancer in the third-line and beyond setting.
- Further research and clinical application are crucial for managing this challenging disease
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle